Werbung
Anlageziel
The objective of the sub-fund is to benefit from the performance of the markets in equities of companies active in the pharmaceuticals, healthcare, medical technologies and biotechnology sectors, by investing in stocks of companies selected by the asset manager on the basis of their expected return, and to outperform the benchmark. This sub-fund invests primarily in equities, and/or securities equivalent to equities, of companies throughout the world which are active in the pharmaceuticals, healthcare, medical technologies and biotechnology sectors. It may also invest in companies with a high proportion of sales relating to the improvement of health conditions.
Stammdaten
Name | Candriam Equities L Life Care BF USD Inc Fonds |
ISIN | LU2223682860 |
WKN | |
Fondsgesellschaft | Candriam |
Benchmark | MSCI World |
Ausschüttungsart | Ausschüttend |
Manager | Servaas Michielssens, Pierre Vaurice, Rudi Van den Eynde |
Domizil | Luxembourg |
Fondskategorie | Aktien |
Auflagedatum | 11.12.2020 |
Geschäftsjahr | 31.12. |
VL-fähig? | Nein |
Depotbank | CACEIS Bank, Luxembourg Branch |
Zahlstelle | CACEIS Bank, Paris, succursale de Nyon / Suisse |
Riester Fonds | Nein |
Basisdaten
Auflagedatum | 11.12.2020 |
Depotbank | CACEIS Bank, Luxembourg Branch |
Zahlstelle | CACEIS Bank, Paris, succursale de Nyon / Suisse |
Domizil | Luxembourg |
Geschäftsjahr | 31.12. |
Aktuelle Daten
Morningstar Rating | |
Aktueller Rücknahmepreis | 1.526,93 |
Anzahl Fonds der Kategorie | 780 |
Volumen der Tranche | 168,03 Mio. USD |
Fondsvolumen | 799,82 Mio. USD |
Total Expense Ratio (TER) | 0,07 |
Gebühren
Laufende Kosten | 0,22% |
Total Expense Ratio (Verwaltungsgebühren & sonst. Kosten) | 0,07% |
Transaktionskosten | 0,15% |
Depotbankgebühr | - |
Managementgebühr | - |
Rücknahmegebühr | - |
Ausgabeaufschlag | - |
Performancedaten
Veränderung Vortag | 16,84 |
WE seit Jahresbeginn | 3,24% |